Note: The comments under each article title are the opinion of our president, Al Musella, DPM, and do not reflect official policy of the Musella Foundation!
02/08/18 Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma.
This trial shows why we need to test treatments in kids and not just assume that they will work the same as in adults. This trial compares the standard of radiation and temodar with and without Avastin, for newly diagnosed high grade glioma. In previously reported trials on adults, there was a pretty good increase in progression free survival with just about no increase in overall survival. In this study with children, they found that adding Avastin decreased both the progression free survival and overall survival, and there were more side effects in the Avastin group.
[Disclosure: Genetech is a sponsor of our organization]
02/03/18 H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis.
This mutation is a bad sign if present. Most DIPG patients have it, and some GBM patients have it. Average survival in an adult Glioblastoma is usually less than half as long as those without it. Luckily, there are a few treatments in the pipeline that target this mutation. ONC201 is one of them - it is in trials for both adult and pediatric brain tumors with this mutation. Too early to tell how it will work but I do know of a few people who did well with it. If you have this mutation but do not fit any of the trials, there may be other ways of getting it. Contact us for help.
02/01/18 Cancer ‘vaccine’ eliminates tumors in mice
This is not in brain tumors yet, but this may be the most exciting news in years. This team has previously invented Rituximab, which is one of the most important cancer drugs ever invented, so they have the experience to do this correctly and quickly.. I am trying to see if we can get it tested on GBMs and/or DIPG.
01/29/18 Optune Open House, Santa Anna, CA
This is from the people at Novocure. These meetings are a perfect introduction to Optune for brain tumor patients thinking about trying it or those who are using it!
01/20/18 Cancer remedy draws patients and criticism
I know nothing about this specific treatment, but it raises a lot of red flags. They refuse to publish results. This could mean one of 2 possibilities:
The treatment doesn't work - so if they publish results, patients would stop going to them and stop giving them $250,000 a treatment. OR - the treatment does work, and by not sharing the results - they are literally killing thousands of patient a year who could benefit from the treatment, if it really did work. Either way, not good.
If it really worked on pediatric DIPG, it would be simple to prove, since the standard treatments do not do so well.
01/10/18 Dr. Kurt Jaeckle to Lead Phase III Clinical Trial of Novel Drug VAL-083 for Late-Stage Glioblastoma
This is a trial for recurrent glioblastoma patients who have failed Temodar and Avastin. There is another trial of Val-083 for newly diagnosed MGMT unmethylated patients. Val-083 is a chemotherapy similar to Temodar but works at a different location on the DNA of the tumor cells. It should theoretically not be affected by the MGMT status and may work even when the tumor is resistant to Temodar